Portfolio News

 

   
December 2014
Oncoethix Exit

SV Life Sciences Fund V notes that Merck acquired Oncoethix from its owners, SV Life Sciences and others, for an upfront payment of $110m. Additional milestone payments of up to $265m are contingent upon clinical and regulatory events being achieved. Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs. .


Merck Press Release


Team - Kate Bingham, Michael Carter

⇧ Back to top